30-Day Notice

33263

Federal Register / Vol. 81, No. 101 / Wednesday, May 25, 2016 / Notices
Correction
In the Federal Register of April 27,
2016, in FR Doc. 2016–09812, the
following corrections are made:
1. On page 24828, in the first column,
under the heading ‘‘Key Dates’’, the
correct Earliest Anticipated Start Date
should read as ‘‘Earliest Anticipated
Start Date: August 15, 2016’’.
2. On page 24829, in the first column,
under the heading ‘‘Project Period’’, the
correct paragraph should read as ‘‘The
project period will be for three (3) years
and will run consecutively from August
15, 2016 to August 14, 2019’’.
Dated: May 11, 2016.
Elizabeth A. Fowler,
Deputy Director for Management Operations,
Indian Health Service.
[FR Doc. 2016–12303 Filed 5–24–16; 8:45 am]
BILLING CODE 4165–16–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Surveys and
Interviews To Support an Evaluation of
the Innovative Molecular Analysis
Technologies (IMAT) Program (NCI)
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Cancer Institute, the National Institutes
of Health, has submitted to the Office of
Management and Budget (OMB) a
request for review and approval of the
information collection listed below.
This proposed information collection
was previously published in the Federal
Register on March 23, 2016, Vol. 81,
Page 15541 and allowed 60-days for
public comment. The purpose of this
notice is to allow an additional 30 days
for public comment. The National
Cancer Institute (NCI), National
Institutes of Health, may not conduct or
sponsor, and the respondent is not
required to respond to, an information
collection that has been extended,

SUMMARY:

presents a rich and unique opportunity
likely to serve institutes across the
National Institutes of Health (NIH), and
perhaps other federal agencies,
considering the costs and benefits of
directing resources towards supporting
technology development. An award
through the NIH Evaluation Set-Aside
program to support this evaluation, for
which NIH-wide relevance is a principle
element of determining merit for
support, is testament to this. The
evaluation serves as an opportunity to
gauge the impact of investments in
technology development and also to
assess the strengths and weaknesses of
phased innovation award mechanisms.
Prior approval from OMB allowed for
extensive surveys and interviews
already, and this extension is requested
to accommodate unforeseen delays in
collecting the remaining information.
Like all institutes and centers (ICs) of
the NIH, NCI seeks opportunities for
improving their programs’ utility for the
broad continuum of researchers,
clinicians and ultimately patients. NCI
Acting Director Douglas Lowy and other
leadership across NCI, as well as the
NCI Board of Scientific Advisors, will
be the primary users of the evaluation
results. Findings are primarily intended
for considering the long-term strategy to
support innovative technology
development and how to more
efficiently translate emerging
capabilities through such technologies
into the promised benefits for cancer
research and clinical care. Interviews
with grantees, program officers, review
officers, and other NIH awardees make
up a crucial component of the
evaluation plan and will largely follow
set survey protocols. Specific near-term
aims include the use of this information
to consider the utility of continued
investment through existing
solicitations and in strategic planning
generally for institute support for
innovative technology development.
OMB approval is requested for 1 year.
There are no costs to respondents other
than their time. The total estimated
annualized burden hours are 233.

revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, OIRA_submission@
omb.eop.gov or by fax to 202–395–6974,
Attention: NIH Desk Officer.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, or request more
information on the proposed project,
contact: Anthony Dickherber, NCI
Center for Strategic Scientific Initiatives,
31 Center Drive, Rm10A33, Bethesda,
MD 20892 or call non-toll-free number
301–547–9980 or Email your request,
including your address to:
[email protected]. Formal
requests for additional plans and
instruments must be requested in
writing.
Proposed Collection: Surveys and
Interviews to Support an Evaluation of
the Innovative Molecular Analysis
Technologies (IMAT) Program (NCI),
0925–0720, Expiration Date 5/31/2016—
EXTENSION, National Cancer Institute
(NCI), National Institutes of Health
(NIH).
Need and Use of Information
Collection: The purpose of the proposed
evaluation is to pursue a comprehensive
process and outcome assessment of the
15-year old Innovative Molecular
Analysis Technologies (IMAT) program.
While the program consistently offers
promising indicators of success, the full
program has not been evaluated since
2008, and never in as comprehensive a
manner as has been formulated in the
current evaluation plan. An outcome
evaluation of the long-standing National
Cancer Institute’s (NCI) IMAT program

mstockstill on DSK3G9T082PROD with NOTICES

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Average
burden per
response
(in hours)

Number of
responses per
respondent

Total annual
burden
(in hours)

Form name

Type of respondents

Interview—IMAT Grantee .................
Web-based
Survey—Technology
Grantees.

18
379

1
1

1
30/60

18
190

Interview—Tech End-Users ..............

IMAT Awardees ................................
IMAT Awardees; Other NIH Awardees
representing
comparison
group.
Technology End-Users .....................

50

1

30/60

25

Totals .........................................

...........................................................

447

447

........................

233

VerDate Sep<11>2014

20:19 May 24, 2016

Jkt 238001

PO 00000

Frm 00066

Fmt 4703

Sfmt 4703

E:\FR\FM\25MYN1.SGM

25MYN1

33264

Federal Register / Vol. 81, No. 101 / Wednesday, May 25, 2016 / Notices

Dated: May 19, 2016.
Karla Bailey,
Project Clearance Liaison, National Cancer
Institute, NIH.
[FR Doc. 2016–12294 Filed 5–24–16; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings

mstockstill on DSK3G9T082PROD with NOTICES

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Cancer, Heart, and Sleep Epidemiology B
Study Section.
Date: June 16–17, 2016.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Rd. NW.,
Washington, DC 20015.
Contact Person: Ellen K Schwartz, EDD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3144,
MSC 7770, Bethesda, MD 20892, 301–828–
6146, [email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Psychosocial Risks and Disease
Prevention.
Date: June 21, 2016.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Weijia Ni, Ph.D., Chief/
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3100,
MSC 7808, Bethesda, MD 20892, 301–594–
3292, [email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Non-HIV Diagnostics, Food Safety,
Sterilization/Disinfection, and
Bioremediation.
Date: June 23–24, 2016.

VerDate Sep<11>2014

20:19 May 24, 2016

Jkt 238001

Time: 8:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton La Jolla Hotel, 3299
Holiday Court, La Jolla, CA 92037.
Contact Person: Gagan Pandya, Ph.D.,
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
Rockledge Drive, RM 3200, MSC 7808,
Bethesda, MD 20892, 301–435–1167,
[email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Non-HIV Microbial Diagnostic and Detection
Research.
Date: June 24, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton La Jolla Hotel, 3299
Holiday Court, La Jolla, CA 92037.
Contact Person: Gagan Pandya, Ph.D.,
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
Rockledge Drive, RM 3200, MSC 7808,
Bethesda, MD 20892, 301–435–1167,
[email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Innovative Immunology Research.
Date: June 24, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Arlington Capital View
Hotel, 2800 South Potomac Ave., Arlington,
VA 22202.
Contact Person: Deborah Hodge, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4207
MSC 7812, Bethesda, MD 20892, (301)435–
1238, [email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Microbiome
and Related Sciences.
Date: June 24, 2016.
Time: 10:30 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott Downtown
Silver Spring, 8506 Fenton Street, Fenton
Street, Silver Spring, MD 20910.
Contact Person: Aiping Zhao, MD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm 2188
MSC7818, Bethesda, MD 20892–7818, (301)
435–0682, [email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR13–231:
Phenotyping Embryonic Lethal Knockout
Mice.
Date: June 24, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Maqsood A Wani, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2114,
MSC 7814, Bethesda, MD 20892, 301–435–
2270, [email protected].

PO 00000

Frm 00067

Fmt 4703

Sfmt 4703

Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Collaborative Applications: Adult
Psychopathology.
Date: June 24, 2016.
Time: 1:00 p.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marines’ Memorial Club and Hotel,
609 Sutter Street, San Francisco, CA 94102.
Contact Person: Serena Chu, Ph.D.,
Scientific Review Officer, BBBP IRG, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3178,
MSC 7848, Bethesda, MD 20892, 301–500–
5829, [email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Alzheimer’s Disease Pilot Clinical Trials.
Date: June 24, 2016.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Mark Lindner, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3182,
MSC 7770, Bethesda, MD 20892, 301–915–
6298, [email protected].
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 19, 2016.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–12295 Filed 5–24–16; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;

E:\FR\FM\25MYN1.SGM

25MYN1